FDA Drug Recalls

Recalls / Class II

Class IID-0178-2024

Product

Doxycycline Capsules, USP 100 mg, 50 Capsules, Rx Only, Manufactured for: Lupin Pharmaceuticals, Inc., Baltimore, Maryland 21202 Unite States; Manufactured by: Lupin Limited, Nagpur - 441 108, INDIA. NDC 68180-652-08

Brand name
Doxycycline
Generic name
Doxycycline
Active ingredient
Doxycycline
Route
Oral
NDCs
68180-650, 68180-651, 68180-652
FDA application
ANDA204234
Affected lot / code info
Batch G104819

Why it was recalled

CGMP Deviations: Products were exposed to temperatures outside of the products labeled storage conditions.

Recalling firm

Firm
CARDINAL HEALTHCARE
Manufacturer
Lupin Pharmaceuticals, Inc.
Notification channel
Letter
Type
Voluntary: Firm initiated
Address
7200 Cardinal Pl W, Dublin, Ohio 43017-1094

Distribution

Quantity
1 unit
Distribution pattern
Nationwide USA

Timeline

Recall initiated
2022-01-26
FDA classified
2023-12-26
Posted by FDA
2024-01-03
Terminated
2024-09-29
Status
Terminated

Source: openFDA Drug Enforcement endpoint. Recall record D-0178-2024. The FDA issues recall classifications as health-hazard assessments, not legal findings; for legal claims consult a licensed attorney.